Curated Information

Javascript is not enabled on this browser. This site will not work properly without Javascript.

Home

Curated Information Page

PubMed Id: 11696579

This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus^®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus^®, click here.

Du XL, et al. (2001) Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 108, 1341-8 11696579

Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.

S1177-p - eNOS (human)

▲

Orthologous residues

eNOS (human): S1177‑p, eNOS (mouse): S1176‑p, eNOS (rat): S1176‑p, eNOS (rabbit): S1183‑p, eNOS (pig): S1179‑p, eNOS (cow): S1179‑p

Characterization

Methods used to characterize site in vivo: mutation of modification site, phospho-antibody

Relevant cell lines - cell types - tissues: BAEC (endothelial)

Cellular systems studied: primary cultured cells

Species studied: cow

Upstream Regulation

Treatments, proteins and their effect on site modification:

Treatments	Referenced Treatments	Effect
hyperglycemia		decrease
hyperglycemia		decrease
wortmannin	hyperglycemia	augment treatment-induced decrease

S1177-g - eNOS (human)

▲

Orthologous residues

eNOS (human): S1177‑g, eNOS (mouse): S1176‑g, eNOS (rat): S1176‑g, eNOS (rabbit): S1183‑g, eNOS (pig): S1179‑g, eNOS (cow): S1179‑g

Characterization

Methods used to characterize site in vivo: mutation of modification site

Relevant cell lines - cell types - tissues: BAEC (endothelial)

Cellular systems studied: cell lines

Species studied: cow

Upstream Regulation

Treatments, proteins and their effect on site modification:

Treatments	Referenced Treatments	Manipulated Protein	Referenced Protein	Effect	Notes
hyperglycemia				increase

S1176-p - eNOS (rat)

▲

Orthologous residues

eNOS (human): S1177‑p, eNOS (mouse): S1176‑p, eNOS (rat): S1176‑p, eNOS (rabbit): S1183‑p, eNOS (pig): S1179‑p, eNOS (cow): S1179‑p

Characterization

Methods used to characterize site in vivo: phospho-antibody

Relevant cell lines - cell types - tissues: vascular

Cellular systems studied: tissue

Species studied: rat

Upstream Regulation

Treatments, proteins and their effect on site modification:

Treatments	Referenced Treatments	Manipulated Protein	Referenced Protein	Effect	Notes
hyperglycemia				decrease

S1179-p - eNOS (cow)

▲

Orthologous residues

eNOS (human): S1177‑p, eNOS (mouse): S1176‑p, eNOS (rat): S1176‑p, eNOS (rabbit): S1183‑p, eNOS (pig): S1179‑p, eNOS (cow): S1179‑p

Characterization

Methods used to characterize site in vivo: phospho-antibody

Relevant cell lines - cell types - tissues: BAEC (endothelial)

Cellular systems studied: primary cultured cells

Species studied: cow

Upstream Regulation

Treatments, proteins and their effect on site modification:

Treatments	Referenced Treatments	Manipulated Protein	Referenced Protein	Effect	Notes
hyperglycemia				decrease
wortmannin	hyperglycemia			augment treatment-induced decrease

Home \| Curator Login	With enhanced literature mining using Linguamatics I2E		Produced by 3rd Millennium \| Design by Digizyme
			©2003-2013 Cell Signaling Technology, Inc.